Archive for the ‘Research’ category

Fostemsavir controls viral load in half of people with highly drug-resistant HIV

October 29, 2017

From aidsmap.com

Fostemsavir, a new experimental attachment inhibitor, suppressed viral load in over half of participants with extensive drug resistance when added to a background regimen selected by resistance testing, Max Lataillade of ViiV Healthcare reported at the 16th European AIDS Conference in Milan on Friday.

The findings come from the phase 3 BRIGHTE study carried out in the United States, France and Brazil.

Fostemsavir (formerly BMS-663068) is a new experimental HIV attachment inhibitor which binds to the HIV gp120 protein, preventing HIV attachment to CD4 cells. Other inhibitors of HIV entry, enfuvirtide and maraviroc, have limited roles in HIV treatment. Enfuvirtide is an HIV fusion inhibitor, an injectable agent that is prescribed only for patients with no other treatment options. Maraviroc is a CCR5 antagonist; it prevents HIV from using the CCR5 receptor on the surface of CD4 cells to gain entry to the cell. It is used in treatment-experienced patients.

Fostemsavir is being developed by ViiV Healthcare as an agent for use in treatment-experienced patients with resistance to several classes of antiretroviral drug. The drug was acquired from Bristol-Myers Squibb along with several other experimental antiretroviral drugs in 2016.

Read the full article.

The WHO public health approach to HIV treatment and care: looking back and looking ahead

October 23, 2017

From the Lancet

In 2006, WHO set forth its vision for a public health approach to delivering antiretroviral therapy. This approach has been broadly adopted in resource-poor settings and has provided the foundation for scaling up treatment to over 19·5 million people. There is a global commitment to end the AIDS epidemic as a public health threat by 2030 and, to support this goal, there are opportunities to adapt the public health approach to meet the ensuing challenges. These challenges include the need to improve identification of people with HIV infection through expanded approaches to testing; further simplify and improve treatment and laboratory monitoring; adapt the public health approach to concentrated epidemics; and link HIV testing, treatment, and care to HIV prevention. Implementation of these key public health principles will bring countries closer to the goals of controlling the HIV epidemic and providing universal health coverage.

Read the full paper here.

 

Lung cancer deaths higher among people living with HIV

September 27, 2017

According to the U.S. National AIDS Strategy report, about 1 in 5 American adults smoke. Among adults living with HIV, the number of people who smoke is 2 to 3 times greater. The report also states that smoking can cause health risks specifically for people who are living with HIV. For example, smokers with HIV are at higher risk (as compared to nonsmokers with HIV) of developing smoking-related cancers, bacterial pneumonia, COPD, heart disease, and oral candidiasis (thrush).

Furthermore, previous research found that HIV-positive smokers lose years of life to cigarettes as compared to nonsmokers with HIV.

If all of that wasn’t enough to convince gay and bi men with HIV to kick the habit, a new study published in The Journal of the American Medical Association narrows the range of research, focusing specifically on projected lung cancer deaths.

The researchers found that nearly 25 percent of people who adhere well to anti-HIV medications but continue to smoke will die from lung cancer. Among smokers who quit at age 40, only about 6 percent will die of lung cancer. The authors also found that people with HIV who take antiviral medicines but who also smoke are from 6 to 13 times more likely to die from lung cancer than from HIV/AIDS.

“Quitting smoking is one of the most important things that people with HIV can do to improve their health and live longer,” Travis Baggett, MD, MPH, of the MGH Division of General Internal Medicine and coauthor of the study, said in a recent press release. “Quitting will not only reduce their risk of lung cancer but also decrease their risk of many other diseases, such as heart attack, stroke and emphysema.”

To read a press release about the study, click here. To find out more about how you can quit smoking, click here and here.  For more information about Health Alerts, go to the Health Alerts page of this Website. To subscribe to the Pitt Men’s Study Health Alerts, send an email to rgy2@Pitt.edu, with the word subscribe in the subject line.

 

Health Alerts are presented by the HIV Prevention and Care Project and the Pitt Men’s Study at the University of Pittsburgh Graduate School of Public Health, with funding from the Pennsylvania Department of Health.

Pitt Men’s Study launching new initiatives in 2017

August 24, 2017

Wondering what’s up with the Pitt Men’s Study?

Principle investigator, Dr. Charles Rinaldo spells it all out in an open letter to the Study’s participants, including detailed information about upcoming research for 2018. Click on a printable PDF file of Dr. Rinaldo’s letter to get all the details.

For more information about the Pitt Men’s Study, contact us at:

Pitt Men’s Study
P.O. Box 7319
Pittsburgh, PA 15213
412-624-2008 or toll-free at 1-800-987-1963
PMS@stophiv.pitt.edu

New injectable antiretroviral treatment proved to be as effective as standard oral therapy

August 6, 2017

From Science Daily

Antiretroviral therapy (ART) intramuscularly administered may have the same effectiveness as current oral treatments. This is the main conclusion of the Phase II clinical trial carried out by 50 centers around the world — 9 in Spain — to which the team of Dr. Daniel Podzamczer, principal investigator of the Bellvitge Biomedical Research Institute (IDIBELL) and Chief of the HIV and STD Unit of the Infectious Diseases Service of Bellvitge University hospital (HUB) has contributed. The results of the trial, published by the journal The Lancet, pave the way to the implantation of all-injectable antiretroviral therapies with a lower frequency of administration, which would imply a significant improvement of the quality of life of HIV patients.

Read the full article.

Dr. Larry Corey of the HIV Vaccine Trials Network talks about what it will take to rid the world of AIDS

May 4, 2017

From Time Health

In many ways, the domestic and global fight against HIV/AIDs has made great strides. Yet there are still millions of people who are newly diagnosed with HIV globally each year.

One preventive strategy receiving renewed attention and progress is an HIV vaccine. Dr. Larry Corey, the principal investigator of the HIV Vaccine Trials Network based at Fred Hutchinson Cancer Research Center, recently launched a highly ambitious HIV vaccine study, which will test a protective antibody on thousands of people around the world.

Dr Corey“I am cautiously optimistic,” said Corey during a panel discussion at Fortune’s Brainstorm Health conference on Tuesday. Corey says researchers could start seeing very early results from the trials as early April 2019.

Beyond a vaccine, getting people rapid treatment is another way to keep infection rates down, and help people with an HIV diagnosis live a long and healthy life. Dr. Diane Havlir, a professor of medicine at the University of California, San Francisco (UCSF), has been part of an innovative program in San Francisco focused on substantially curb the spread of HIV in the city. A key pillar of the program’s success lies in its strategy to get recently infected people into treatment on the same day as their diagnosis.

“We need to work together in order to reduce the number of HIV infections,” said Havlir during the conference, adding that getting patients into treatment quickly can help empower them to take charge of their treatment. It’s also an inexpensive strategy.

But what will it take to get to zero infections worldwide? Both Corey and Havlir said public commitment and cross sector engagement will be critical. “For sure, HIV is the epidemic of our time,” said Corey. “I think to some extent the health care of our generation is going to be defined by how we handle [it] … We need sustained commitment.”

Havlir agrees. “Invest in research. Invest in care. Either we pay now, or we pay later,” she said.

Watch the video interview here.

Addressing stigma, coping behaviors and mechanisms in persons living with HIV could lead to better health outcomes

April 25, 2017

From medicalxpress.com

Investigators from the University of Alabama at Birmingham have developed a new conceptual framework highlighting how unique dimensions of individual-level HIV-related stigma might affect the health of those living with HIV. According to the paper’s authors, little is known about the mechanisms through which stigma leads to worse health behaviors or outcomes.

The framework, published in the American Journal of Public Health, looks at perceived community stigma, experienced stigma, internalized stigma and anticipated stigma as barriers to both HIV prevention and engagement in care. An intersectional framework looks at how multiple social statuses intersect at an individual level, such as HIV status, race, gender or sexual orientation, and a broader level, such as structural stigmas in society including racism, sexism, HIV-related stigma and classism, to produce health inequalities.

The conceptual framework suggests that individual-level dimensions of HIV-related stigma operate through interpersonal factors, mental health, psychological resources and biological stress pathways.

“Those living with HIV often fight fear and experiences of HIV-related stigma, affecting their quality of life and mental health, as well as engaging poorly in their HIV care and treatment,” said Janet Turan, Ph.D., professor in the UAB School of Public Health Department of Health Care Organization and Policy. “Our proposed conceptual framework for individual-level dimensions of stigma and potential individual and interpersonal mechanisms explains how stigma affects each individual’s HIV-related health.”

HIV-infected individuals may be judged by others to be in marginalized social groups, causing social stress because of their minority social position, which could lead to important implications for their health.

Read more at: https://medicalxpress.com.